Drug Trial Radar · NCT06235775
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Dec 12, 2023
Primary completion
Sep 1, 2025
Study completion Sep 1, 2025
Sponsor
- Lead sponsor
- GemVax & KaelIndustry
- Sponsor type
- Industry
- First posted
- Feb 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 41 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will be conducted by the Sponsor to evaluate Twelve-months Long-Term Safety and Efficacy of GV1001 (1.12 mg) administered subcutaneously as a treatment for Progressive Supranuclear Palsy(PSP). In 75 patients diagnosed with PSP Richardson(PSP-RS) or PSP-Parkinsonism (PSP-P) who Completed Study GV1001-PSP-CL2-011.
Conditions
- Progressive Supranuclear Palsy
Interventions
GV1001 PlaceboDrug
0.9% normal saline
GV1001 1.12mgDrug
Lyophilized peptide from hTERT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventTime frame: 12 months
- Change in Hematological tests WBC(10^3/µl)Time frame: 12 months
- Change in Hematological tests RBC(10^6/µl)Time frame: 12 months
- Change in Hematological tests Hemoglobin(g/dL)Time frame: 12 months
- Change in Hematological tests Hematocrit(%)Time frame: 12 months
- Change in Hematological tests Platelets count(10^3/µl)Time frame: 12 months
- Change in Hematological tests WBC differential count (Neutrophils(%))Time frame: 12 months
- Change in Hematological tests WBC differential count( Lymphocytes(%))Time frame: 12 months
- Change in Hematological tests WBC differential count( Monocytes(%))Time frame: 12 months
- Change in Hematological tests WBC differential count(Eosinophils(%))Time frame: 12 months
- Change in Hematological tests WBC differential count(Basophils(%))Time frame: 12 months
- Change in Hematochemical tests BUN(mg/dL)Time frame: 12 months
- Change in Hematochemical tests Creatinine(mg/dL)Time frame: 12 months
- Change in Hematochemical tests Uric acid(mg/dL)Time frame: 12 months
- Change in Hematochemical tests Total bilirubin(mg/dL)Time frame: 12 months
- Change in Hematochemical tests Albumin(g/dL)Time frame: 12 months
- Change in Hematochemical tests Total Protein(g/dL)Time frame: 12 months
- Change in Hematochemical tests ALT(U/L)Time frame: 12 months
- Change in Hematochemical tests AST(U/L)Time frame: 12 months
- Change in Hematochemical tests γ-GTP(U/L)Time frame: 12 months
- Change in Hematochemical tests Alkaline phosphatase(U/L)Time frame: 12 months
- Change in Hematochemical tests Glucose(mg/dL)Time frame: 12 months
- Change in Hematochemical tests Total Cholesterol(mg/dL)Time frame: 12 months
- Change in urine tests Protein-Albumin(mg/dL)Time frame: 12 months
- Change in urine tests Glucose(mg/dL)Time frame: 12 months
- Change in urine tests Ketones(mg/dL)Time frame: 12 months
- Change in urine tests WBC(HPF)Time frame: 12 months
- Change in urine tests Blood-RBC(HPF)Time frame: 12 months
- Blood Pressure (mmHG)Time frame: 12 months
- Pulse rate(beats per min)Time frame: 12 months
- Respiratory rate(breaths per min)Time frame: 12 months
- temperature(℃)Time frame: 12 months
- EKGTime frame: 12 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Kyung Hee University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.